NASDAQ · VERU
Veru Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VERU: Dec 16, 2026
Veru Inc. Common Stock is estimated to report earnings on 12/16/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.34.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.34 | $-0.34 | $-0.34 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Fintel · Zacks- RTTNews · Sep 8, 11:18 AM EDTVeru Advances Sabizabulin Toward Phase 2b Trial In Daraxonrasib-Resistant Pancreatic Cancer(RTTNews) – Veru Inc. (VERU) announced positive preclinical data showing that oral sabizabulin demonstrated potent anticancer activity against pancreatic cancer cells resistant to daraxonrasib (RASONQUE), supporting the company's decision to advance the drug candidate into a plan
- The Motley Fool · Aug 17, 7:58 AM EDTVeru (VERU) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 10, 1:52 PM EDTVeru Gains 17% As Obesity Trial Exceeds Enrollment Target, Data Due In Q1, 2027(RTTNews) – Shares of Veru Inc. (VERU) are up 17.17% today, following financial results for its fiscal 2026 third quarter ended June 30, 2026, and an update on the progress of its clinical development programs.
- RTTNews · Jul 28, 2:16 AM EDTVeru Completes Phase 2b Enrollment For Enobosarm In Treating Obesity(RTTNews) – Veru Inc. (VERU), a late clinical-stage biopharmaceutical company, on Monday announced full enrollment in the Phase 2b Plateau study evaluating oral Enobosarm with Semaglutide in older adults with obesity. The study will assess the combination's effect on total body w
- RTTNews · Jun 4, 10:42 PM EDTTop Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA…(RTTNews) – Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business; Absci, ahead of clinical trial readouts; and Alvotech, which is taking another shot at FDA app
- The Motley Fool · May 13, 2:48 PM EDTVeru (VERU) Q2 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · Feb 11, 8:53 AM ESTVeru (VERU) Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Feb 4, 5:05 PM ESTVeru (VERU) Price Target Increased by 11.11% to 25.50The average one-year price target for Veru (NasdaqCM:VERU) has been revised to $25.50 / share. This is an increase of 11.11% from the prior estimate of $22.95 dated January 11, 2026. The price target is an average of many targets provided by analysts. The late
- Fintel · Dec 18, 7:05 PM ESTCanaccord Genuity Initiates Coverage of Veru (VERU) with Buy RecommendationFintel reports that on December 18, 2025, Canaccord Genuity initiated coverage of Veru (NasdaqCM:VERU) with a Buy recommendation. Analyst Price Forecast Suggests 850.66% Upside
- Zacks · Aug 15, 9:20 AM EDTVeru Announces Novel Modified-Release Oral Formulation for EnobosarmVERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
- RTTNews · Aug 6, 9:37 AM EDTVeru Sets 1-for-10 Reverse Stock Split(RTTNews) – Veru Inc. (VERU), a late clinical stage biopharmaceutical company, Wednesday announced a 1-for-10 reverse stock split, effective August 8.
- RTTNews · Jun 24, 9:05 AM EDTWhy Veru Inc. Is Rising In Pre-market?(RTTNews) – Veru Inc. (VERU) announced positive topline efficacy and safety results from the maintenance extension portion of the Phase 2b QUALITY clinical study. The company said the Phase 2b Maintenance Extension clinical trial showed that in 12 weeks after stopping semaglutid
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Veru Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.